Author s response to reviews
|
|
- Milton Pierce
- 6 years ago
- Views:
Transcription
1 Author s response to reviews Title: Multipoint Pacing versus conventional ICD in Patients with a Narrow QRS complex (MPP Narrow QRS trial): study protocol for a pilot randomized controlled trial Authors: Maurizio Gasparini (maurizio.gasparini@humanitas.it) Paola Galimberti (paola.galimberti@humanitas.it) Renato Bragato (renato.bragato@humanitas.it) Stefano Ghio (S.Ghio@smatteo.pv.it) Claudia Raineri (C.Raineri@smatteo.pv.it) Maurizio Landolina (maurizio.landolina02@gmail.com) Enrico Chieffo (Enrico.chieffo@asst-crema.it) Maurizio Lunati (maurizio.lunati@ospedaleniguarda.it) Ederina Mulargia (ederina.mulargia@ospedaleniguarda.it) Alessandro Proclemer (proclemer.alessandro@aoud.sanita.fvg.it) Domenico Facchin (facchin.domenico@aoud.sanita.fvg.it) Roberto Rordorf (r.rordorf@smatteo.pv.it) Alessandro Vicentini (alessandro.vicentini@libero.it) Lina Marcantoni (lina.marcantoni@gmail.com) Francesco Zanon (franc.zanon@iol.it) Catherine Klersy (klersy@smatteo.pv.it) Version: 1 Date: 09 Nov 2016 Author s response to reviews: We sincerely thank the referees for their reviews, and feel that their observations have enabled us to improve the quality of our manuscript.
2 All the issues raised have been addressed and the text has been modified accordingly. We hope that our replies and the modifications we have made will be deemed appropriate by the reviewers. A point-by-point list of modifications is enclosed. In addition, please note the following: 1. All authors of this manuscript were involved in the following activities: - Study design and data analysis - Drafting and revising of the manuscript - Final manuscript approval. 2. This manuscript is not being considered for publication elsewhere. 3. None of the manuscript contents have been published elsewhere. 4. All authors have read and approved this manuscript. Once again, thank you for considering our manuscript. Sincerely, Maurizio Gasparini Reviewer #1: Gasparini and colleagues submitted a study protocol for a feasibility randomized controlled trial (pilot study) to compare a novel method of cardiac resynchronization therapy (CRT) based on multipoint pacing (MPP) with standard ICD, in patients with heart failure and indication for ICD and 100 ms < QRS < 130 ms, in promoting reverse left ventricular remodeling at 12 months. The study is interesting and relevant, and based on appropriate methods. The protocol is overall well written and clear. However some revisions should be made, concerning the study rationale and question, missing information about methods, and correctness and clarity of some statements. #1 Study rationale and question
3 As it is designed, the study implies a research question embedding in fact 2 questions: i) whether a CRT might work also in the case of narrow QRS, and ii) whether MPP might work in case of narrow QRS. As a consequence if the study fails to show any effect of MPP-based CRT compared with standard ICD with no CRT, this might be due either to the fact that a CRT does not work in the case of narrow QRS or that MPP does not work but a CRT differently implemented could still work. The reviewer would suggest: a. that authors comment on this study implication in the Discussion b. that authors help the reader to better understand the rationale for their study, in particular the rationale for testing a MPP-based CRT instead of a standard biventricular stimulation. It would help if evidence on the effect of biventricular stimulation in patients with narrow QRS (i.e. QRS prolongation) currently mentioned in Discussion (page 8, lines , "Aranda et al. ( ) with a narrow QRS[5]) was in fact moved to the Introduction section. Answer: We thank the reviewer for this comment. This is the crucial point. In patients with narrow QRS, CRT is not currently indicated as standard practice. Moreover, patients with a QRS between 100 and 130 are in a grey zone. In the light of the Echo-CRT study results, the new guidelines do not suggest implanting a CRT device in this category of patients. However, Multipoint-pacing has recently become available and has proved to be a novel CRT technology based on a different kind of pacing (from two cathodes at different delays). Literature on MPP is now also available and this suggests that the new modality is promising in patients who do not respond to CRT. We have inserted these points into the article: -page 9 line 234 Moreover, the Echo CRT study, which enrolled patients with systolic heart failure and a QRS duration < 130 ms, found that CRT did not reduce the rate of death or hospitalization [8]. Since the publication of this study, the CRT on the system guidelines have been changed -page 9, line 244 The first studies on this new technology seem to underline [11,12,13,14] an increase in responders and a reduction in QRS duration in MPP patients. Molhoek et al. [33] demonstrated that Baseline QRS was not predictive of response; however, responders showed a significant reduction in QRS duration directly after initiation of CRT, and this was maintained during follow-up. - As you suggested, we have moved the sentences "Aranda et al. ( ) with a narrow QRS[5] from page 8, lines , to the Introduction section. #2 Inclusion criteria. The reviewer could not find in the manuscript any explicit descriptions of which are the "standard indications to ICD". It should be included.
4 Answer: Thank you for underlining this missing explanation. For greater clarity, we have inserted the indication on page 5 line : All the enrolled patients must be indicated for ICD implantation in accordance with the current guidelines.[3] (An ICD is recommended in order to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA Class II III) and an LVEF 35% despite 3 months of optimal medical therapy, provided they are expected to survive substantially longer than one year with good functional status). #3 Randomization and Blindness. The manuscript is currently lacking for important information concerning the randomization procedure (what method will be used? will be centralized or local?) and concerning blindness (who will be blinded to allocation? patients, investigators, outcome assessors, statisticians, etc.?). Answer: we have reported this information in Study Population and Randomization : randomization will be centralized by means of an online tool and a database created for this study. The allocation process will be blinded to the investigators and carried out by an external assessor (CRO). The investigators will not be blinded to the treatment groups after randomization. Importantly, the Echo data will be analyzed by a central echo core lab, which will be blinded to allocation. #4 Outcomes. All primary and secondary outcomes are in fact surrogate/intermediate outcomes. Why not to choose patient-important outcomes (e.g. measures of patient's performance, arrhythmias, hospitalization, mortality)? Would them be included in the final larger trial? This choice would deserve a comment. Answer: We thank the reviewer for this comment. We chose to use echo parameters, as in the previous studies on multipoint pacing [Optimization of left ventricular pacing site plus multipoint pacing improves remodeling and clinical response to cardiac resynchronization therapy at 1 year, Zanon, HR 2016]. Moreover, Yu CM et al. demonstrated that CRT responders who displayed LV reverse remodeling (defined as a reduction in LV end-systolic volume by >15%) showed an improvement in clinical status, cardiac function and systolic synchronicity [Predictors of left ventricular reverse remodeling after cardiac resynchronization therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopathy, Yu CM]. In another study Yu CM et al. demonstrated that a reduction in LVESV of 10% is a strong predictor of lower long-term mortality and heart failure events. [Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Yu CM, Circulation 2005] In the study database we will collect information on hospitalization, arrhythmias and mortality. These data are not included as endpoints because this is a pilot feasibility study with a small simple size. However, these data are very important, and it is indispensable to point out that these outcomes will be the key to evaluating patient responsiveness in a future larger trial. While MPP efficacy cannot be evaluated as a hard endpoint in a pilot study, it could be evaluated in a large trial with an adequate sample size.
5 #5 Sample size calculation. The authors calculate their pilot's size adopting the approach proposed by Cock et al (J Clin Epidemiol 2013). This is a very interesting and rigorous approach, however: a. It is not clear why the authors chose 23% as a "clinically significant" effect size; where did it come from? please, clarify. b. In following and quoting the paper by Cock et al., there are sentences that sound incorrect: I. Page 7, lines 156-7: "( ) interested in whether the hypothesized treatment estimate of 23% is larger than, or equal to, the upper limit of the 90% CI computed under the null hypothesis". Should this in fact be "interested in whether the hypothesized treatment estimate is larger or equal/smaller than 0"? a. Page 7, lines 158-9: "( ) and the upper limit of the one-sided 90% confidence interval excludes the clinically relevant effect size of 23%". Should this in fact be "( ) and the upper limit of the one-sided 90% confidence interval excludes the clinically relevant effect size of 23% under the null hypothesis". Answer: A 20% difference in the proportion of success is generally considered of clinical interest in heart failure trials; a 15% reduction is the change in LVESV accepted as indicating LV remodeling. Also, an unpublished analysis of the group of patients enrolled in the CERTIFY REGISTRY (Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation and The CERTIFY Study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry); Gasparini et al, JACC HF-2013) presenting a QRS duration ms showed that CRT may determine LV reverse remodeling in 23% of these cases. b. We completely agree with the referee s correction; this was an error that has now been corrected in the manuscript. Thank you for pointing it out. #6 Table 1 should be reformatted with the "Inclusion criteria (A)" placed before the "Exclusion criteria (B)". Answer: the table has been reformatted Rev.2 I read with pleasure the MPP Narrow QRS manuscript of this randomized trial protocol. As it has been externally reviewed and the recruitment already started, I minimize my suggestions. In order to agree with Trials policy and to facilitate further readings, please, provide the SPIRIT table specifying where is reported any item.
6 Answer: Thank you for the suggestion to add the Spirit table. We report the Table in a separate sheet and we have inserted clearer information in the article. Background: we have expanded the introduction section. Trial Design: we have added the Study Population and Randomization chapter. Please, add that final report will follow CONSORT as well as their extensions for nonpharmacological interventions and pilot trials. Please, note that the former requires additional items not stated in SPIRIT; and that it provides important considerations about blinding. You are proposing an adaptive design. Answer: Thank you for the suggestion, we have modified the report to follow CONSORT for non-pharmacological interventions and pilot trials. About the blinding and randomization process, we will include some statements in the article. Please, state if it has been approved by a regulatory agency. Answer: the study has been approved by Ethics Committee Please, provide either the rationale or the evidence to guarantee that alpha risk is maintained at some desired level. Answer: The method takes into consideration the upper confidence limit of the clinical gain reached with 90% probability (then the alpha error accepted is 10% that is typical in pilot studies) In L148 you anticipate some attrition. It seems to me too high for patients with implantable devices -even with a long follow up. Please, consider to distinguish between deaths and losses. Answer: We consider 10% of attrition, as in a previous CRT device study design [Muto et al., Narrow QRS Study]. In this study, the final results showed a 13% drop out rate (in both groups): 10% of deaths and 3% of losses to follow-up. In the Madit CRT study, an annual death rate of approximately 3% in each study group (ICD vs CRTD) was reported [Arthur J. Moss et al. Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events- NEJM 2009]
Bi-Ventricular pacing after the most recent studies
Seminars of the Hellenic Working Groups February 18th-20 20,, 2010, Thessaloniki, Greece Bi-Ventricular pacing after the most recent studies Maurizio Lunati MD Director EP Lab & Unit Cardiology Dpt. Niguarda
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationBENEFIT OF CRT IN MILDLY SYMPTOMATIC HEART FAILURE RECENT DATA FROM MADIT-CRT AND RAFT
BENEFIT OF CRT IN MILDLY SYMPTOMATIC HEART FAILURE RECENT DATA FROM MADIT-CRT AND RAFT Ilan Goldenberg MD Professor of Cardiology Sheba Medical Center and Tel Aviv University, Israel University of Rochester
More informationArthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY. DISCLOSURE INFORMATION Arthur J.
Saving Lives and Preventing Heart Failure: The MADIT Family of Trials Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY Update in Electrocardiography
More informationCardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital
More informationResponse of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT
Response of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT Heart Rhythm Society (May 11, 2012) Colin L. Doyle, BA,*
More informationDevices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine
Devices and Other Non- Pharmacologic Therapy in CHF Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine Disclosure None University of Miami vs. OSU Renegade Miami football
More informationThe Role of ICD Therapy in Cardiac Resynchronization
The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine
More informationMADIT Studies: CRT in the Non-LBBB Patient and Other Findings. Arthur J. Moss, MD
MADIT Studies: CRT in the Non-LBBB Patient and Other Findings Arthur J. Moss, MD University of Rochester Medical Cntr. Rochester, NY 13 th Annual New Frontiers in Heart Failure Rx NYC, NY January 26, 2013
More informationLarge RCT s of CRT 2002 to present
Have We Expanded Our Use of CRT for Heart Failure Patients? Sana M. Al-Khatib, MD, MHS Associate Professor of Medicine Electrophysiology Section- Division of Cardiology Duke University Potential Conflicts
More informationComparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure
HOT TOPIC Cardiology Journal 2010, Vol. 17, No. 6, pp. 543 548 Copyright 2010 Via Medica ISSN 1897 5593 Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart
More informationCRT Vs RV Pacing Benefits
CRT-P & CRT-D Indications According to Guidelines are Guidelines Fully Adopted? Salama H. Omar M.D. Prof. Critical Care Medicine, Cairo University CRT Vs RV Pacing Benefits 1 Benefit of Upgrade CTR-P &
More informationΕνδείξεις αμφικοιλιακής βηματοδότησης. Ποιοι ασθενείς με καρδιακή ανεπάρκεια πρέπει να λάβουν αμφικοιλιακό απινιδωτή;
Ενδείξεις αμφικοιλιακής βηματοδότησης. Ποιοι ασθενείς με καρδιακή ανεπάρκεια πρέπει να λάβουν αμφικοιλιακό απινιδωτή; Άννα Κωστοπούλου Επιμελήτρια Α Ωνάσειο Καρδιοχειρουργικό Κέντρο Τμήμα Ηλεκτροφυσιολογίας
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationBSH Annual Autumn Meeting 2017
BSH Annual Autumn Meeting 2017 Presentation title: The Development of CRT Speaker: John GF Cleland Conflicts of interest: I have received research support and honoraria from Biotronik, Boston Scientific,
More informationGender and cardiac resynchronization therapy. Chairs: David Heaven & Belinda Green. Gender and Cardiac Resynchronisation Therapy
Electrophysiology Gender and cardiac resynchronization therapy Dean Boddington Chairs: David Heaven & Belinda Green Gender and Cardiac Resynchronisation Therapy Dean Boddington Tauranga Hospital 1 Disclosure/Warning
More informationThe Role of Ventricular Electrical Delay to Predict Left Ventricular Remodeling With Cardiac Resynchronization Therapy
The Role of Ventricular Electrical Delay to Predict Left Ventricular Remodeling With Cardiac Resynchronization Therapy Results from the SMART-AV Trial Michael R. Gold, MD, PhD, Ulrika Birgersdotter-Green,
More informationCardiac Resynchronization ICD Therapy: What is New?
Cardiac Resynchronization ICD Therapy: What is New? Emile Daoud, MD Section Chief, Cardiac Electrophysiology Professor of Medicine The Ohio State University Normal Activation, Narrow QRS Synchrony Abnormal
More informationA Square Peg in a Round Hole: CRT IN PAEDIATRICS AND CONGENITAL HEART DISEASE
A Square Peg in a Round Hole: CRT IN PAEDIATRICS AND CONGENITAL HEART DISEASE Adele Greyling Dora Nginza Hospital, Port Elizabeth SA Heart November 2017 What are the guidelines based on? MADIT-II Size:
More informationHeart failure and sudden death
Heart failure and sudden death What did we learn so far from important ICD- and CRT trials? Helmut U. Klein M.D. University of Rochester Medical Center Heart Research Follow up Program Arrhythmic substrate
More informationIndications for and Prediction of Successful Responses of CRT for Patients with Heart Failure
Indications for and Prediction of Successful Responses of CRT for Patients with Heart Failure Edmund Keung, MD Clinical Chief, Cardiology Section San Francisco VAMC October 25, 2008 Presentation Outline
More informationCONTAK RENEWAL CLINICAL SUMMARY
CAUTION: Federal law restricts this device to sale by or on the order of a physician trained or experienced in device implant and follow-up procedures. CLINICAL SUMMARY CONTAK RENEWAL Boston Scientific
More informationThis is What I do to Improve CRT Response for CRT Non-Responders
This is What I do to Improve CRT Response for CRT Non-Responders Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Steering Committees (unpaid) and Clinical Trials,
More informationCRT-P or CRT-D From North Alberta to Nairobi
CRT-P or CRT-D From North Alberta to Nairobi Dr Mzee Ngunga Aga Khan University Hospital Nairobi KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web:
More informationUSE OF ACCELEROMETER DATA TO EVALUATE PHYSICAL ACTIVITY AS A SURROGATE ENDPOINT IN HEART FAILURE CLINICAL TRIALS. Tracy Bergemann PhD
USE OF ACCELEROMETER DATA TO EVALUATE PHYSICAL ACTIVITY AS A SURROGATE ENDPOINT IN HEART FAILURE CLINICAL TRIALS Tracy Bergemann PhD Senior Principal Statistician ASA Biopharmaceutical Section Regulatory-Industry
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationCardiac resynchronization therapy for heart failure: state of the art
Cardiac resynchronization therapy for heart failure: state of the art Béla Merkely MD, PhD, DSc, FESC, FACC Vice president of the European Society of Cardiology Honorary president of the Hungarian Society
More informationCRT-D or CRT-P: HOW TO CHOOSE THE RIGHT PATIENT?
CRT-D or CRT-P: HOW TO CHOOSE THE RIGHT PATIENT? Alessandro Lipari, MD Chair and Department of Cardiology University of Study and Spedali Civili Brescia -Italy The birth of CRT in Europe, 20 years ago
More informationPercutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat
Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Innovative Procedures, Devices & State of the Art Care for Arrhythmias, Heart Failure & Structural Heart Disease October 8-10,
More informationDevice Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx
Device Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx Charles Gottlieb, MD Director of Electrophysiology Abington Memorial Hospital Heart Failure Mortality Mechanism of death
More informationImportance of CRT team for optimization of the results: a European point of view
Importance of CRT team for optimization of the results: a European point of view Matteo Bertini, MD, PhD Arcispedale S. Anna Azienda Ospedaliero-Universitaria Cona-Ferrara No conflict of interest to declare
More informationHow do I convert my CRT Non Responder into Responder?
How do I convert my CRT Non Responder into Responder? Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting Boston Scientific, Medtronic
More informationHeart Failure Overview. Dr Chris K Y Wong
Heart Failure Overview Dr Chris K Y Wong Heart Failure: A Growing, Global Health Issue Heart Failure 23 Million Afflicted Global Impact Worldwide ~23 million peopleworldwide afflicted with CHF 1 Exceeds
More informationESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309
ESC Guidelines Update 2008 ESC Guidelines Heart failure update 2008 For internal training purpose. 0 Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC
More informationSummary, conclusions and future perspectives
Summary, conclusions and future perspectives Summary The general introduction (Chapter 1) of this thesis describes aspects of sudden cardiac death (SCD), ventricular arrhythmias, substrates for ventricular
More informationDo All Patients With An ICD Indication Need A BiV Pacing Device?
Do All Patients With An ICD Indication Need A BiV Pacing Device? Muhammad A. Hammouda, MD Electrophysiology Laboratory Department of Critical Care Medicine Cairo University Etiology and Pathophysiology
More informationCatheter-based mitral valve repair MitraClip System
Percutaneous Mitral Valve Repair: Results of the EVEREST II Trial William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular
More informationDevice based CRT optimization: is there a future? Lessons learned from published trials
Device based CRT optimization: is there a future? Lessons learned from published trials C. Leclercq Department of Cardiology Centre Cardio-Pneumologique Rennes, France Presenter Disclosure Information
More informationThe road to successful CRT implantation: The role of echo
The road to successful CRT implantation: The role of echo Tae-Ho Park Dong-A University Hospital, Busan, Korea Terminology Cardiac Resynchronization Therapy (CRT) = Biventricular pacing (BiV) = Left ventricular
More informationDisclosures: Drs. Bristow, Saxon, Boehmer, Kass, and Feldman are consultants to Guidant (sponsor) HFSA Late-Breaker September 24, 2003
Cardiac Resynchronization Therapy (CRT) Reduces Hospitalizations, and CRT with Implantable Defibrillator (CRT-D) Reduces Mortality in Chronic Heart Failure: The COMPANION Trial Bristow MR,(Co-Ch) Feldman
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationIs QRS width predictive of the clinical and echocardiographic response to chronic CRT in mildly symptomatic HF patients?
Is QRS width predictive of the clinical and echocardiographic response to chronic CRT in mildly symptomatic HF patients? Data from REVERSE C Thébault 1, M Gold 2, C Linde 3, WT Abraham 4, C Leclercq 1,
More informationHeart Failure Overview. Dr Chris K Y Wong
Heart Failure Overview Dr Chris K Y Wong Heart Failure: A Growing, Global Health Issue Heart Failure 23 Million Afflicted Global Impact Worldwide ~23 million peopleworldwide afflicted with CHF 1 Exceeds
More informationQu attendre de la technologie pour un meilleur suivi? (traitement) D Gras, MD, Nantes, France
Qu attendre de la technologie pour un meilleur suivi? (traitement) D Gras, MD, Nantes, France New Technologies in CRT How do they impact daily clinical practice? Septal CRT Dual-Site LV CRT Quadripolar
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationCardiac Resynchronization Therapy. Michelle Khoo, MD
Cardiac Resynchronization Therapy Michelle Khoo, MD 10.7.08 HuiKuri HV NEJM 2001 Sudden Death (SD) in Subset Populations HuiKuri HV NEJM 2001 Sudden Death (SD) in Subset Populations SD in Competitive Athletes
More informationPredictive Power of the Baseline QRS Complex Duration for Clinical Response to Cardiac Resynchronisation Therapy
CARDIAC RESYNCHRONISATION THERAPY ORIGINAL ARTICLE Predictive Power of the Baseline QRS Complex Duration for Clinical Response to Cardiac Resynchronisation Therapy Ali Kazemisaeid, MD, Ali Bozorgi, MD,
More informationHF and CRT: CRT-P versus CRT-D
HF and CRT: CRT-P versus CRT-D Andrew E. Epstein, MD Professor of Medicine, Cardiovascular Division University of Pennsylvania Chief, Cardiology Section Philadelphia VA Medical Center Philadelphia, PA
More information14ο Βορειοελλαδικό Καρδιολογικό Συνέδριο ΚΕΒΕ Βηματοδότηση: Νεότερες εξελίξεις Προοπτικές
14ο Βορειοελλαδικό Καρδιολογικό Συνέδριο ΚΕΒΕ Βηματοδότηση: Νεότερες εξελίξεις Προοπτικές Α.Γ. Κατσίβας Συντονιστής Διευθυντής, Α Καρδιολογική Κλινική, ΓΝΑ «Κοργιαλένειο-Μπενάκειο Ε.Ε.Σ» BRADY - ARRHYTHMIA
More informationIt has been shown from meta-analysis of randomized clinical trials that patients with a pre-crt QRS duration (QRSD) >150 ms benefit
Cardiac Resynchronization Therapy may be detrimental in patients with a Very Wide QRSD > 180 ms (VWQRSD) and Right Bundle Branch Block Morphology: Analysis From the Medicare ICD Registry Varun Sundaram
More informationInvestigator Initiated Study Proposal Form
Please submit completed form to IISReview@KCI1.com Date Submitted Name & Title Institution Address Phone Number Email Address Principal Investigator / Institution YES NO Multi Center Study Acelity Product(s)
More informationCardiac Resynchronization Therapy Guidelines and Missing Groups
Cardiac Resynchronization Therapy Guidelines and Missing Groups Frank Pelosi, Jr., MD, FACC, FHRS Director, Cardiac Electrophysiology Fellowship Associate Professor of Medicine University of Michigan Health
More informationCardiac Resynchronization Therapy for Heart Failure
Cardiac Resynchronization Therapy for Heart Failure Ventricular Dyssynchrony vs Resynchronization Ventricular Dysynchrony Ventricular Dysynchrony 1 Electrical: Inter- or Intraventricular conduction delays
More informationHis Bundle Pacing in Bundle Branch Block May 11, 2017
His Bundle Pacing in Bundle Branch Block May 11, 2017 Gopi Dandamudi, MD FHRS System Medical Director, IUH Cardiac EP Program Director, IUH Atrial Fibrillation Center Assistant Professor of Clinical Medicine
More informationESC CONGRESS HIGHLIGHTS ARRHYTHMIAS. M. Bertini (Ferrara, IT) Conflicts of Interest none
ESC CONGRESS HIGHLIGHTS ARRHYTHMIAS M. Bertini (Ferrara, IT) Conflicts of Interest none Data that may change daily practice... Atrial fibrillation OACs in real life - BEYOND program Halvorsen S 2951 OAC
More informationEBR Systems, Inc. 686 W. Maude Ave., Suite 102 Sunnyvale, CA USA
Over 200,000 patients worldwide are estimated to receive a CRT device each year. However, limitations prevent some patients from benefiting. CHALLENGING PROCEDURE 5% implanted patients fail to have coronary
More informationLeft Ventricular Ejection Fraction >35%
Controversies in Cardiac Resynchronisation Therapy Left Ventricular Ejection Fraction >35% Professor John GF Cleland University of Hull Kingston-upon-Hull United Kingdom Conflict of Interest: I have received
More informationICD Guidelines: who benefits from an ICD?
ICD Guidelines: who benefits from an ICD? Matthew Bennett Cardiac Electrophysiologist Vancouver Coastal Health, Device Lead Associate Professor, UBC Matthew.bennett@vch.ca Disclosures I have research collaborations
More informationThe SEPTAL CRT study (NCT: )
Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators The SEPTAL CRT study (NCT: 00833352) Christophe
More informationEuropean Federation of Statisticians in the Pharmaceutical Industry (EFSPI)
Page 1 of 14 European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) COMMENTS ON DRAFT FDA Guidance for Industry - Non-Inferiority Clinical Trials Rapporteur: Bernhard Huitfeldt (bernhard.huitfeldt@astrazeneca.com)
More informationImplantable cardioverter-defibrillators and cardiac resynchronization therapy
Implantable cardioverter-defibrillators and cardiac resynchronization therapy Johannes Holzmeister, MD University Hospital Zurich, Zurich, Switzerland Frontiers of heart failure controversies, ESC - Paris
More informationMADIT-RIT: Simple programming change averts most inappropriate ICD therapy
Print MADIT-RIT: Simple programming change averts most inappropriate ICD therapy NOV 6, 2012 Steve Stiles Los Angeles, CA - A large randomized trial has identified specific programming criteria for implantable
More informationPredictive Power of the Baseline QRS Complex Duration for Clinical Response to Cardiac Resynchronisation Therapy
CARDIAC MARKERS ORIGINAL RESEARCH Predictive Power of the Baseline QRS Complex Duration for Clinical Response to Cardiac Resynchronisation Therapy Ali Kazemisaeid, MD, Ali Bozorgi, MD, Ahmad Yamini Sharif,
More informationRisk Stratification of Sudden Cardiac Death
Risk Stratification of Sudden Cardiac Death Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: None Sudden Cardiac Death A Major Public Health Problem > 1/2 of
More informationPERFORMANCE MEASURE TECHNICAL SPECIFICATIONS. HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate
PERFORMANCE MEASURE TECHNICAL SPECIFICATIONS HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate Measure Title Description Measure Type Data Source Level of Analysis Numerator HRS-3:
More informationBiventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure
Last Review Status/Date: June 2015 Page: 1 of 29 Resynchronization Therapy) for the Treatment Description Cardiac resynchronization therapy (CRT), which consists of synchronized pacing of the left and
More informationDRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials
DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials EFSPI Comments Page General Priority (H/M/L) Comment The concept to develop
More informationProvocative Cases: Issues in the Expanding Use of CRT in Treating CHF Patients
Provocative Cases: Issues in the Expanding Use of CRT in Treating CHF Patients David E. Krummen, MD Associate Professor of Medicine University of California San Diego and VA San Diego Healthcare System
More informationCecilia Linde Karolinska University Hospital Stockholm
The mildly symptomatic patient with low EF, moderate/severe mitral regurgitation and QRS 140 ms Cecilia Linde Karolinska University Hospital Stockholm Presenter Disclosure Information Cecilia Linde, MD,
More informationAll in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)
More informationPrimary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
More informationHow atrial fibrillation should be treated in the heart failure patient?
Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 13/15 Ottobre 2016 How atrial fibrillation should be treated in the heart failure patient? Matteo Anselmino Dipartimento Scienze
More informationRisk prediction in inherited conditions Laminopathies
Risk prediction in inherited conditions Laminopathies Karim Wahbi Cochin hospital, Paris karim.wahbi@aphp.fr Risk prediction in laminopathies Current approach for risk stratification A new score to predict
More informationEffect of Ventricular Pacing on Myocardial Function. Inha University Hospital Sung-Hee Shin
Effect of Ventricular Pacing on Myocardial Function Inha University Hospital Sung-Hee Shin Contents 1. The effect of right ventricular apical pacing 2. Strategies for physiologically optimal ventricular
More informationLONG-TERM SURVIVAL WITH CARDIAC RESYNCHRONIZATION THERAPY IN MILD HEART FAILURE PATIENTS
LONG-TERM SURVIVAL WITH CARDIAC RESYNCHRONIZATION THERAPY IN MILD HEART FAILURE PATIENTS Ilan Goldenberg, MD, Valentina Kutyifa, MD, PhD, Helmut Klein, MD, Scott McNitt, MA, Mary Brown, MA, Arthur J. Moss,
More informationLONGITUDINAL SURVEILLANCE REGISTRY OF ACUITY SPIRAL LEAD
CLINICAL SUMMARY LONGITUDINAL SURVEILLANCE REGISTRY OF ACUITY SPIRAL LEAD CAUTION: Federal law restricts this device to sale by or on the order of a physician trained or experienced in device implant and
More informationEndpoints When Treating VT/VF in Patients with ICDs Programming Wojciech Zareba, MD, PhD
Endpoints When Treating VT/VF in Patients with ICDs Programming Wojciech Zareba, MD, PhD Professor of Cardiology/Medicine Director of the Heart Research Follow Up Program, University of Rochester, Rochester,
More informationThoranis Chantrarat MD
Device Therapy in Heart Failure Thoranis Chantrarat MD 1 Scope of presentation Natural history of heart failure Primary and secondary prevention ICD and its indication CRT and its indication 2 Severity
More informationDipartimento di Scienze Cardiovascolari Università Campus Bio-Medico di Roma Dott. Vito Calabrese
Dipartimento di Scienze Cardiovascolari Università Campus Bio-Medico di Roma Dott. Vito Calabrese Because the primary objective was cure symptomatic bradicardya due to syncope Because this is the common
More information8/8/2011. CARDIAC RESYCHRONIZATION THERAPY for Heart Failure. Case Presentation. Case Presentation
CARDIAC RESYCHRONIZATION THERAPY for Heart Failure James Taylor, DO, FACOS Cardiothoracic and Vascular surgery San Angelo Community Medical Center San Angelo, TX Case Presentation 64 year old female with
More informationMultisite Left Ventricular Pacing for Cardiac Resynchronization
Multisite Left Ventricular Pacing for Cardiac Resynchronization C. W. Israel, M.D. Ass. Prof. Dept. of Medicine Cardiology Evangelical Hospital Bielefeld Germany J. W. Goethe University Frankfurt C.W.Israel@em.uni-frankfurt.de
More informationResynchronization/Defibrillation
Resynchronization/Defibrillation for Ambulatory Heart Failure Trial Cardiac Resynchronization Therapy for Mild to Moderate Heart Failure George Wells University of Ottawa Heart Institute Department of
More informationThe Role of Exercise in Management of Patients with Heart Failure
The Role of Exercise in Management of Patients with Heart Failure Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Chair, ACC Prevention of Cardiovascular Disease Leadership Council and Section Director,
More informationBiomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D.
Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D. Professor of Medicine Division of Cardiology University of California, San Diego Disclosures Honoraria, Research Grants, Medtronic Honoraria,
More informationI NON RESPONDERS ALLA CRT: UN PROBLEMA DI NON SEMPLICE SOLUZIONE
I NON RESPONDERS ALLA CRT: UN PROBLEMA DI NON SEMPLICE SOLUZIONE Gaetano Senatore S.C. CARDIOLOGIA OSPEDALE DI CIRIE & OSPEDALE DI IVREA LABORATORIO di Today s Patient Selection for CRT +AF and PM patients
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationThe Mitral Revolution: Transcatheter Repair (and Replacement?) Going Mainstream
The Mitral Revolution: Transcatheter Repair (and Replacement?) Going Mainstream Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org
More informationFirst question: Does CRT Work in AF?
CRT in AF Does it work and when to ablate AF versus AV node Maurizio Gasparini Chief EP and Pacing Unit Humanitas Research Hospital, Rozzano - Milano, Italy First question: Does CRT Work in AF? As any
More informationCRT response: definition and handling of non-responders
CRT response: definition and handling of non-responders Maurizio Gasparini Chief of Electrophysiology and Pacing Unit IRCCS, Istituto Clinico Humanitas, Rozzano- Italy Definition of non-responders First
More informationSCOMPENSO CARDIACO: IL PUNTO DELLA RICERCA
Journal Club 19 Marzo 2010 SCOMPENSO CARDIACO: IL PUNTO DELLA RICERCA Alessandro Giordano Prevalence of heart failure by sex and age (NHANES:1999-2004) Circulation 2007 Incidence of heart failure by age
More informationBiventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure
Last Review Status/Date: September 2016 Page: 1 of 29 Resynchronization Therapy) for the Treatment Description Cardiac resynchronization therapy (CRT), which consists of synchronized pacing of the left
More informationName of Policy: Bi-Ventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure
Name of Policy: Bi-Ventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure Policy #: 055 Latest Review Date: April 2014 Category: Surgery Policy Grade: A Background/Definitions:
More informationCardiac Resynchronisation Therapy for all Patients Requiring Ventricular Pacing
Cardiac Resynchronisation Therapy for all Patients Requiring Ventricular Pacing Philippe Mabo University Hospital, Rennes, France ESC Congress 2010, Stockholm 29 Aug 2010 Which Patients? Candidate for
More informationCRT: whom does it benefit?
CRT: whom does it benefit? Francisco Leyva BSH Revalidation and Training 2018 Queen Elizabeth Hospital NICE guidelines for CRT LVEF 35% NYHA class I II III IV QRS
More informationESC/EHRA. Guidelines on Cardiac Pacing. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece
ESC/EHRA Guidelines on Cardiac Pacing Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Reasons for European Guidelines? Scientific reasons Cultural and political reasons
More informationDevice Therapy for Heart Failure
Device Therapy for Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics St Boniface General Hospital,
More informationCardiac resynchronization therapy for mild-to-moderate heart failure
For reprint orders, please contact reprints@expert-reviews.com Cardiac resynchronization therapy for mild-to-moderate heart failure Expert Rev. Med. Devices 8(3), 313 317 (2011) Haran Burri Electrophysiology
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationHow to treat Cardiac Resynchronization Therapy complications? C. Leclercq Departement of Cardiology Centre Cardio-Pneumologique Rennes, France
How to treat Cardiac Resynchronization Therapy complications? C. Leclercq Departement of Cardiology Centre Cardio-Pneumologique Rennes, France Presenter Disclosure Information Christophe Leclercq, MD,
More informationJACC: Heart Failure Vol. 1, No. 6, 2013 Ó 2013 by the American College of Cardiology Foundation ISSN /$36.00
Ó 2013 by the American College of Cardiology Foundation ISSN 2213-1779/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jchf.2013.06.003 Cardiac Resynchronization Therapy in Patients With
More information